Lexicon Pharma (LXRX) Misses Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $1.46 +1.39%
Revenue Growth %: -79.9%
Financial Fact:
Subscription and license fees: 31K
Today's EPS Names:
UVV, SII, SCKT, More
Revenue Growth %: -79.9%
Financial Fact:
Subscription and license fees: 31K
Today's EPS Names:
UVV, SII, SCKT, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q2 EPS of ($0.07), $0.02 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $28.9 million versus the consensus estimate of $4 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi raises Keurig Dr Pepper price target to $40
- Adyen NV (ADYEN:NA) (ADYYF) PT Lowered to EUR1,046 at Deutsche Bank
- Rosenblatt Reiterates Buy Rating on Arista Networks (ANET)
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
